6YG Stock Chart & Stats
€31.40
-€0.60(-1.94%)
At close: 4:00 PM EDT
€31.40
-€0.60(-1.94%)
Day’s Range― - ―
52-Week Range€23.20 - €35.60
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€1.43B
Enterprise Value€1.17K
Total Cash (Recent Filing)€880.21M
Total Debt (Recent Filing)€434.96M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Nov 11, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding51,498,615
10 Day Avg. Volume15
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)4.59
Price to Sales (P/S)5.87
P/FCF Ratio-156.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.23Price Target Upside72.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€388.38M
Bulls Say, Bears Say
Bulls Say
Strong Revenue ScalingRapid revenue expansion demonstrates increasing commercial adoption and meaningful business scale. Continued growth can improve operating leverage, support broader investment in the pipeline, and strengthen Immunocore’s ability to build a durable commercial biotechnology franchise.
Exceptionally High Gross MarginsExceptionally high and stable gross margins indicate favorable product-level economics for the marketed therapy and related business. These margins provide substantial potential to convert future revenue growth into operating improvement once development spending and other costs are covered.
Phase 3 Expansion OpportunityCompleting enrollment in the randomized Phase 3 TEBE-AM trial creates a defined clinical milestone that could expand KIMMTRAK beyond its current uveal melanoma indication. A positive survival readout would broaden the addressable market and reinforce the company’s oncology position.
Bears Say
Persistent Net LossesThe company has not yet reached consistent profitability despite substantial revenue growth. Ongoing net losses reduce internally generated capital, leave less financial room for pipeline investment, and make successful execution of commercial and clinical programs important to future earnings improvement.
Elevated LeverageElevated leverage increases the financial obligations attached to the company’s growth strategy and limits flexibility if operating performance weakens. Combined with ongoing losses, higher debt exposure can constrain capital allocation and increase execution risk as additional funding needs arise.
Renewed Cash BurnNegative operating and free cash flow in the latest TTM indicates that the business is not yet self-funding its operations and expansion. Persistent cash burn may require continued financing until profitability and cash conversion stabilize, potentially limiting flexibility across commercial and pipeline priorities.
Immunocore Holdings News
6YG FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was €23.20 and its highest was €35.60 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is €1.43B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Nov 11, 2026 which is in 55 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Aug 06, 2026. The company reported -€0.017 earnings per share for the quarter, missing the consensus estimate of €0.009 by -€0.026.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.1.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 51,498,615 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -€0.017 in its last earnings report, missing expectations of €0.009. Following the earnings report the stock price went up 2.098%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in DE:6YG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€54.23 (72.70% Upside)
€54.23 (72.70% Upside)
Blogger Sentiment
Neutral
DE:6YG Sentiment 50%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.42%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunocore Holdings
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
6YG Company Deck
6YG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong commercial execution for KIMTRAK (29% YoY revenue growth to $400M), broad global adoption (39 approvals, 30 launches), meaningful real-world survival and duration signals, a diversified pipeline anchored by three Phase 3 trials with near-term readouts, and a solid cash position (~$864M). Balanced against this are expected revenue-growth moderation in 2026, rising R&D investment, event-driven timing uncertainty for key OS trials, small early-stage cohorts (HIV), and competitive/operational risks tied to trial geography and evolving treatment options. Overall, the company presents momentum and optionality but with important clinical and timing risks that will be clarified by upcoming data readouts.View all DE:6YG earnings summaries6YG Stock 12 Month Forecast
Average Price Target
€54.23
▲(72.70% Upside)